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Loss-of-Function Variants of the Filaggrin Gene Are
Not Major Susceptibility Factors for Psoriasis Vulgaris
or Psoriatic Arthritis in German Patients
Ulrike Hu¨ffmeier1, Heiko Traupe2, Vinzenz Oji2, Jesu´s Lascorz1, Markward Sta¨nder3, Jo¨rg Lohmann4,
Jo¨rg Wendler5, Harald Burkhardt6 and Andre´ Reis1
Psoriasis vulgaris and atopic dermatitis share a number of features such as chronic cutaneous inflammation and
disturbed epidermal barrier function. Genome-wide scans have revealed a conspicuous overlap of
susceptibility loci for both diseases involving chromosomal regions 1q21, 3q21, 17q25, and 20p12. Recently,
two loss-of-function variants in the gene encoding filaggrin at 1q21 were shown to be strongly associated with
atopic dermatitis. In view of a possible genetic overlap of the two skin diseases, we investigated 375 patients
suffering from psoriasis vulgaris, 375 patients with psoriatic arthritis, and 376 control probands. Moreover we
directly studied expression of filaggrin in 10 patients suffering from psoriasis vulgaris. Our immunohisto-
chemical analysis revealed a checkered pattern with alternating positive broadened or almost absent filaggrin
expression. However, no association was found for the two variants of filaggrin (FLG). We conclude that despite
a markedly altered filaggrin expression in psoriatic skin, loss-of-function variants of the FLG gene are neither
associated with psoriasis vulgaris nor with psoriatic arthritis. The abnormal staining might reflect the altered
epidermal differentiation. Our findings imply that the genetic background underlying the epidermal barrier
defect in psoriasis is distinct from that found in atopic dermatitis.
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INTRODUCTION
Atopic dermatitis and psoriasis vulgaris are chronic and
relapsing diseases of the skin. Common further hallmarks are
impaired epidermal barrier and profound cutaneous inflam-
mation (Ghadially et al., 1996; Sator et al., 2003; Segre,
2006). Although both diseases share the inflammatory aspect,
the regulation of inflammatory cells and chemokines is
oppositional. It is known that disruption of the epidermal
barrier can stimulate keratinocytes to produce inflammatory
cytokines such as tumor necrosis factor-a, IFN-g, IL-1, and
GM/CSF (Nickoloff and Naidu, 1994; Wood et al., 1997).
Recently, it was published that epidermal barrier deficits and
psoriasis-like skin disease can result from abrogation of Jun
proteins (Zenz et al., 2005).
Interestingly, genome-wide linkage scans performed in the
quest for genetic factors contributing to each disorder
revealed a significant overlap of chromosomal regions
harboring potential susceptibility loci, for example, chromo-
somal regions 1q21, 3q21, 17q25, and 20p12. This lead to
the hypothesis, that both diseases share at least some genetic
factors. (Cookson et al., 2001). To date though, most of
disease causing variants or corresponding genes at these
susceptibility loci have not been identified in either disorder.
Two loss-of-function mutations in the gene encoding
filaggrin (FLG), an epidermal barrier protein, localized at
chromosome 1q21.3, were very recently shown to cause the
common form of ichthyosis (ichthyosis vulgaris) (Smith et al.,
2006), and atopic dermatitis (Palmer et al., 2006). These
findings highlighted the pathophysiological concept of a
barrier function deficit increasing susceptibility to atopic
dermatitis. Considering the overlap of psoriasis vulgaris and
atopic dermatitis with regard to inflammation and possibly
genetic factors, more so as the location of FLG coincides
with one of the psoriasis susceptibility loci (PSORS4), we
were interested whether the two FLG variants identified
might compromise the barrier function in psoriasis vulgaris,
as well. Furthermore, we studied expression of filaggrin in a
number of skin biopsies of psoriasis patients in comparison to
normal skin and to a skin biopsy of a patient with ichthyosis
vulgaris.
RESULTS
The immunohistochemical study revealed an altered filaggrin
expression in eight out of 10 skin sections of psoriasis vulgaris
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Abbreviation: FLG, filaggrin
patients (Figure 1c–e) whereas two skin sections showed a
normal granular filaggrin signal in the uppermost layers of the
epidermis (Figure 1d). Interestingly, in skin of two psoriasis
vulgaris patients (Figure 1c) the filaggrin signal was almost
completely missing, reminiscent of the situation in ichthyosis
vulgaris (Figure 1b). Most psoriasis vulgaris skin sections
(n¼6) revealed an alternating staining pattern of almost
negative and broadened positive parts of the upper epidermal
layers (‘‘checker board-like’’) implying a markedly altered
expression of filaggrin (Figure 1e). Interestingly, a similar
staining pattern was also observed for loricrin (data not
shown).
Genotyping was successful in 98.1% and in 95.7% of
probands with regard to R501X and 2282del4, respectively.
We did not observe deviation from Hardy–Weinberg in any of
the study groups for either variant.
Table 1 gives an overview of the allele frequencies in the
different study groups and the corresponding results of allele
frequency difference tests. The combined frequency of the
two risk alleles in our population-based controls of 4.6% was
similar to the previously described combined Caucasian
cohort (Palmer et al., 2006, Table S1), whereas the frequency
of allele *501X was slightly lower and the frequency of
*2282del4 slightly higher in our study group of population-
based controls. These differences were not significant,
though. In either of our patient groups, the total number of
the two different risk alleles was nominally lower than in
control probands. In contrast to genotypes of control
individuals, one patient of each patient study group was
homozygous for the risk allele of 2282del4 and one proband
with psoriasis vulgaris was homozygous for the *501X allele.
In none of our probands we observed compound hetero-
zygosity. Given the similar frequencies in all three study
groups, association of psoriasis vulgaris or of psoriatic
arthritis with R501X or 2282del4 was not found.
DISCUSSION
Investigation of deficits of epidermal barrier function and its
genetic background is a promising approach for clarifying the
molecular pathology of the two skin diseases atopic
dermatitis and psoriasis vulgaris, which can be characterized
by disturbed epidermal differentiation and cutaneous inflam-
mation. The immunohistochemical analysis of filaggrin at the
epidermal layers showed an abnormal expression pattern in
the majority of patients with psoriasis vulgaris with areas of
accentuated or diminished staining. Interestingly, two skin
sections exhibited an almost complete lack of filaggrin
expression comparable to that found in ichthyosis vulgaris.
The observed checkered expression pattern of filaggrin in
psoriasis vulgaris might reflect the disturbed epidermal
differentiation. Loricrin – being also an important component
of the cornified envelope (Kalinin et al., 2002) and therefore a
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Figure 1. Expression of filaggrin. Expression of filaggrin in (a) normal skin, (b) ichthyosis vulgaris and (c–e) psoriasis vulgaris. (a) Healthy skin shows a strong
granular cytoplasmic staining of filaggrin antigen encompassing 3–4 cell layers of the stratum granulosum (SG). (b) In contrast, ichthyosis vulgaris skin of a
patient heterozygous for R501X exhibits a marked reduction of filaggrin. Note the residual ‘‘dotted’’ filaggrin signal in the SG. (c) This psoriasis vulgaris skin
shows a strongly reduced signal for filaggrin. (d) Two psoriasis vulgaris patients demonstrated a normal staining pattern. (e) Most psoriasis vulgaris skin sections
(6 out of 10) exhibited a ‘‘checker board-like’’ (checkered) pattern with alternating positive broadened and almost negative filaggrin expression. Bars¼ 20mM.
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late differentiation marker similar to filaggrin – showed a
resembling alternating pattern of broadened and diminished
staining. Our findings confirm the results of previous
investigations and underline the presence of disturbed
epidermal barrier in psoriasis (van der Vleuten et al., 1996).
However, our genetic analyses suggest that the two FLG
variants associated with atopic dermatitis do not play a major
role in the etiology of psoriasis vulgaris and psoriatic arthritis,
at least in the German population. Genetic heterogeneity,
though, has to be taken into account, therefore we cannot
exclude that this might be different in other populations,
although it seems unlikely based on the similarity of
association results reported from several European popula-
tions. Still, our study does not exclude any role of filaggrin in
the pathogenesis of psoriasis vulgaris. But the genetic
background underlying the epidermal barrier defect in
psoriasis seems to be distinct from that found in atopic
dermatitis. With regard to our results of altered expression of
epidermal genes, other genes involved in barrier function
might be good candidate genes for psoriasis.
Even though colocalization of susceptibility loci for these
two skin diseases has been suggested for several years now,
no mutual gene has been identified. At PSORS2, a RUNX1-
binding site was associated in different study groups of
psoriasis (Helms et al., 2003) whereas this was not replicated
in several further studies of psoriasis patients (Huffmeier
et al., 2005b; Stuart et al., 2006); furthermore the risk allele
was not associated in a large study group of families with
atopic dermatitis phenotype (Morar et al., 2006).
In the future, studies at other susceptibility loci/ genes will
identify disease-causing variants for either psoriasis or atopic
dermatitis, allowing verification whether psoriasis and atopic
dermatitis share common genetic contributors.
MATERIALS AND METHODS
Immunohistochemistry
For studies of immunofluorescence, 4mM unfixed cryosections were
blocked with 10% normal goat serum for 30 minutes, then incubated
with mouse anti-filaggrin (1:100 in phosphate-buffered saline;
Novocastra, Newcastle upon Tyne, UK), or rabbit anti-loricrin
(1:2,500; PRB-145P, BabCo, Berkeley, CA) for 20 hours at þ 71C.
The primary antibody was visualized with FITC-goat anti-mouse IgG
or with FITC-goat anti-rabbit IgG, both diluted 1:200 in phosphate-
buffered saline (Jackson ImmunoResearch Laboratories, Inc. West
Grove, PA). Slides were viewed with an Axioscope 2 and digital
images taken using an Axiocam HR video camera and Axiovision
3.0 software (all Carl Zeiss, Jena, Germany).
Genetic analyses
We investigated two case–control studies comprising 375 patients
with psoriasis vulgaris, 375 patients with psoriatic arthritis and 376
healthy blood donors. The study groups have been described
previously (Huffmeier et al., 2005a, 2006). The studies were
approved by the ethical committees of the University of Erlangen-
Nuremberg and of the University of Mu¨nster. Written informed
consent was obtained from each patient and control proband before
enrolment. The investigations were conducted according to the
Declaration of Helsinki Principles.
Genotyping of the variant R501X was performed with a TaqMan
assay (Applied Biosystems, Foster City, USA) on a 7900HT Taqman
(ABI), the deletion of four base pairs (2282del4) as size-based
analysis of PCR fragments on an Applied Biosystems 3100
sequencer. Both genotyping methods were conducted as described
by Palmer et al. (2006). TaqMan genotypes could be confirmed
through direct sequencing in a set of 24 randomly chosen probands.
Statistical analyses were performed to determine significant differ-
ences in allele frequencies between groups of patients and controls.
As the number of expected observations was low, Fisher’s exact test
was performed.
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